Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216

. 2017 Oct ; 17 (5) : 452-460. [epub] 20160830

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid27573236

The Hedgehog pathway is one of the major driver pathways in pancreatic ductal adenocarcinoma. This study investigated prognostic importance of Hedgehog signaling pathway in pancreatic cancer patients who underwent a radical resection. Tumors and adjacent non-neoplastic pancreatic tissues were obtained from 45 patients with histologically verified pancreatic cancer. The effect of experimental taxane chemotherapy on the expression of Hedgehog pathway was evaluated in vivo using a mouse xenograft model prepared using pancreatic cancer cell line Paca-44. Mice were treated by experimental Stony Brook Taxane SB-T-1216. The transcript profile of 34 Hedgehog pathway genes in patients and xenografts was assessed using quantitative PCR. The Hedgehog pathway was strongly overexpressed in pancreatic tumors and upregulation of SHH, IHH, HHAT and PTCH1 was associated with a trend toward decreased patient survival. No association of Hedgehog pathway expression with KRAS mutation status was found in tumors. Sonic hedgehog ligand was overexpressed, but all other downstream genes were downregulated by SB-T-1216 treatment in vivo. Suppression of HH pathway expression in vivo by taxane-based chemotherapy suggests a new mechanism of action for treatment of this aggressive tumor.

Zobrazit více v PubMed

Nature. 2008 Sep 18;455(7211):406-10 PubMed

Anticancer Res. 2009 Aug;29(8):2951-60 PubMed

Mol Cancer. 2010 Jul 14;9:192 PubMed

Clin Cancer Res. 2014 Dec 1;20(23 ):5937-5945 PubMed

Mol Cancer Ther. 2009 Feb;8(2):310-4 PubMed

J Med Chem. 2008 Jun 12;51(11):3203-21 PubMed

Methods. 2001 Dec;25(4):402-8 PubMed

J Biol Chem. 2013 Apr 26;288(17 ):11786-94 PubMed

Virchows Arch. 2001 Dec;439(6):798-802 PubMed

J Gastrointest Oncol. 2013 Dec;4(4):370-3 PubMed

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5103-8 PubMed

J Natl Cancer Inst. 2015 Jan 31;107(2):null PubMed

N Engl J Med. 2013 Oct 31;369(18):1691-703 PubMed

Cancer Cell. 2014 Jun 16;25(6):735-47 PubMed

Clin Lung Cancer. 2016 Jul;17 (4):301-8 PubMed

Cancer Chemother Pharmacol. 2013 Sep;72 (3):669-82 PubMed

Nature. 2012 Nov 15;491(7424):399-405 PubMed

Cancers (Basel). 2015 Aug 11;7(3):1554-85 PubMed

J Pharmacol Pharmacother. 2013 Jan;4(1):4-7 PubMed

J Clin Invest. 2012 Feb;122(2):639-53 PubMed

Clin Chem. 2009 Apr;55(4):611-22 PubMed

Drugs. 1994 Nov;48(5):794-847 PubMed

Nature. 2003 Oct 23;425(6960):851-6 PubMed

CA Cancer J Clin. 2013 Jan;63(1):11-30 PubMed

Science. 2008 Sep 26;321(5897):1801-6 PubMed

Cancer Res. 2004 Sep 1;64(17 ):6071-4 PubMed

Stem Cells. 2005 Oct;23(9):1417-22 PubMed

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3091-100 PubMed

Genes Dev. 2006 Nov 15;20(22):3161-73 PubMed

Nat Commun. 2015 Apr 09;6:6744 PubMed

Pancreas. 2013 May;42(4):707-16 PubMed

Carcinogenesis. 2013 Oct;34(10):2361-9 PubMed

Dis Markers. 2012;32(3):203-10 PubMed

J Clin Oncol. 2011 Dec 1;29(34):4548-54 PubMed

Oncotarget. 2016 Apr 26;7(17):24179-93 PubMed

PLoS One. 2012;7(7):e40611 PubMed

PLoS One. 2013 Sep 24;8(9):e69884 PubMed

Invest New Drugs. 2012 Jun;30(3):991-1002 PubMed

Clin Cancer Res. 2015 Mar 1;21(5):1215-24 PubMed

Najít záznam

Citační ukazatele

Možnosti archivace